Elevated levels of fibroblast growth factor 23 (FGF-23) have been demonstrated in tumors from patients with oncogenic osteomalacia and in patients with X-linked hypophosphatemia, leading to increased urinary phosphate loss [2]. Here, FGF23 is linked to osteomalacia.